Trials / Completed
CompletedNCT02922426
An Insulin Sensitivity Study in Healthy Subjects
A Randomized, Double-Blind, Parallel-Group Study in Healthy Subjects to Characterize Insulin Sensitivity and Lipid Metabolism in Response to Treatment With ALKS 3831 and Olanzapine
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Alkermes, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
This study will characterize insulin sensitivity in response to treatment with ALKS 3831, olanzapine, and placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALKS 3831 | Daily dosing for 21 consecutive days |
| DRUG | Olanzapine | Daily dosing for 21 consecutive days |
| DRUG | Placebo | Daily dosing for 21 consecutive days |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-07-20
- Completion
- 2017-07-20
- First posted
- 2016-10-04
- Last updated
- 2017-08-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02922426. Inclusion in this directory is not an endorsement.